Skip to main content
Elsevier

Neurobiology of Depression

Road to Novel Therapeutics

  • 2nd Edition - March 1, 2027
  • Latest edition
  • Editors: João L. de Quevedo, Mario Juruena, Carlos A. Zarate
  • Language: English

Neurobiology of Depression: Road to Novel Therapeutics, Second Edition follows the success of the first edition, synthesizing the basic neurobiology of major depressive disord… Read more

Description

Neurobiology of Depression: Road to Novel Therapeutics, Second Edition follows the success of the first edition, synthesizing the basic neurobiology of major depressive disorder (MDD) with discussions on the latest research advances, including interacting pathways implicated in the pathophysiology of MDD, omics technologies, genetic approaches, and novel optogenetic techniques revolutionizing depression research. This new edition includes comprehensive foundational understandings of the disorder and highlights recent advances, aiding advanced students and researchers in their understanding of MDD. The book introduces new chapters exploring groundbreaking topics such as the neurobiology of treatment-resistant depression, the antidepressant mechanisms of ketamine, and the link between depression and Alzheimer's disease. Additionally, it covers the neurobiology of suicide in depression, the impact of psychedelics as therapy, and the unique aspects of bipolar depression. This edition also examines computational models in depression, the neurobiology of psychotherapy, and the putative mechanisms of action for vagus nerve stimulation as a therapeutic approach. These additions help to provide a broader and more comprehensive understanding of depression and its treatment.

Key features

  • Features new chapters on emerging topics in depression research
  • Explores major depressive disorder (MDD) within the framework of the NIMH Research Domain Criteria (RDoC) recommendations
  • Covers a wide array of existing and potential pharmacologic and non-pharmacologic treatment options
  • Synthesizes discussions on the cellular and molecular mechanisms underlying depressive symptoms with clinical aspects

Readership

Advanced students and researchers in neuroscience, psychology, medicine, health sciences, and pharmacology

Table of contents

1. The Classification of Depression: Embracing Phenotypic Heterogeneity in the Era of the RDoC

2. Incidence, Prevalence, and Global Burden of Depression

3. The Role of Environmental and Psychosocial Factors in Depression

4. Gene-Environment Interactions and Epigenetic Mechanisms in Depression

5. Pathophysiology of Cognitive Impairment in Depression

6. Anhedonia in Depression: Mechanisms, Assessment, and Therapeutics

7. The Neurotrophic Hypothesis of Depression Revisited: New Insights and Therapeutic Implications

8. The Monoamine Hypothesis of Depression Revisited: Could It Lead to Mechanistically Novel Antidepressant Strategies?

9. Neuro-Immune Interactions in Depression: Mechanisms and Translational Implications

10. The Hypothalamic-Pituitary-Adrenal Axis in Depression: Molecular Regulation, Pathophysiological Role, and Translational Implications

11. Intracellular Signalling Pathways Implicated in the Pathophysiology of Depression

12. The Long-Lasting Neurobiological Scars of Early-Life Stress: Implications for the Neurobiology of Depression

13. Molecular, Cellular, and Circuit Basis of Depression Susceptibility and Resilience

14. More Than a Gut Feeling: Emerging Roles of the Microbiome in the Pathophysiology and Treatment of Depression

15. Optogenetics: Illuminating the Neural Circuits of Depression

16. Mitochondrial Dysfunction and Oxidative Stress: Relevance to the Pathophysiology and Treatment of Depression

17. Obesity and Depression: Shared Pathophysiology and Translational Implications

18. Neurobiology of Antidepressant-Induced Weight Gain

19. Depression and Cardiovascular Risk: Epidemiology, Mechanisms, and Implications

20. Poststroke Depression: Pathophysiology and Treatment Strategies

21. Is Depression Associated with Accelerated Aging? Mechanisms and Implications

22. Relationship Between Complicated Grief and Depression: Relevance, Etiological Mechanisms, and Implications

23. Understanding the Neurobiology of Depression through Structural Neuroimaging

24. A Neural Circuit-Based Model for Depression Anchored in a Synthesis of Insights from Functional Neuroimaging

25. Could Depression Be Preventable? Evidence and Perspectives

26. Treating Depression in the Era of Precision Medicine: Challenges and Perspectives

27. Neurobiological Aspects of Functional Recovery in Major Depressive Disorder

28. Diet and Depression: From Epidemiology to Novel Therapeutics

29. Physical Activity and Exercise as a Treatment of Depression: Evidence and Neurobiological Mechanism

30. Antidepressants and Suicidality—Controversies and Possible Mechanisms

31. Altered GABAergic Function, Cortical Microcircuitry, and Information Processing in Depression

32. Implications of Pharmacogenomics in Depression Pathophysiology and Treatment

33. Novel Neuromodulatory Approaches for Depression: Neurobiological Mechanisms

34. Electroconvulsive Therapy for Depression: Neurobiological Mechanisms

35. Putative Mechanism of Action for Vagus Nerve Stimulation as Therapeutic for Depression

36. Deep Brain Stimulation: Mechanisms Underpinning Antidepressant Effects

37. Novel Therapeutic Targets for Major Depressive Disorder

38. The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives

39. Neurobiology of Child and Adolescent Depression

40. Neurobiology of Depression in Women

41. Biological Basis of Late-Life Depression

42. Advances in Early Age Depression

43. What Makes Ketamine a Better Antidepressant?

44. Neurobiology of Suicide in Depression

45. Neurobiology of Depression as a Risk Factor for Alzheimer's Disease

46. Neurobiology of Treatment-Resistant Depression

47. Understanding the Mechanism of Action of Psychedelics as Therapy for Depression

48. Neurobiology of Bipolar Depression

49. Computational Models in Depression

50. Neurobiology of Psychotherapy for Depression

Product details

  • Edition: 2
  • Latest edition
  • Published: March 1, 2027
  • Language: English

About the editors

Jd

João L. de Quevedo

João L. de Quevedo, MD, Ph.D., obtained his Medical Degree and completed residency training in Psychiatry, a fellowship in Psychopharmacology, and a Ph.D. in Biological Sciences (Biochemistry), all from the Federal University of Rio Grande do Sul, Porto Alegre, Brazil. He is the John S. Dunn Distinguished Professor at the Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston). He also serves as Professor, Vice-Chair for Faculty Development and Outreach, Executive Director of the Center for Interventional Psychiatry, Chief of the Division of Interventional Psychiatry, Director of the Treatment-Resistant Depression Program, and Program Director of the Interventional Psychiatry Fellowship. Dr. Joao L. de Quevedo is an Associate Editor for Molecular Psychiatry, a Springer Nature journal.

Research profiles:

ResearcherID: E-5491-2013

Scopus Author ID: 56971689500

https://orcid.org/0000-0003-3114-6611

Affiliations and expertise
Professor and John S. Dunn Distinguished Professor; Executive Director, Center for Interventional Psychiatry, McGovern Medical School at UTHealth Houston, Houston, Texas, United States

MJ

Mario Juruena

Mario Juruena, MD, PhD, is Professor of Affective Disorders and Translational Psychiatry at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, within the Centre for Affective Disorders, Department of Psychological Medicine. He is also a Consultant Psychiatrist at South London and Maudsley NHS Foundation Trust (SLaM) and the National Affective Disorders Service. He currently leads the Maudsley Advanced Treatment Service (MATS) for Difficult-to-Treat Depression and Bipolar Disorders and the Maudsley ECT Service.

Affiliations and expertise
Professor of Affective Disorders and Translational Psychiatry at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK

CZ

Carlos A. Zarate

Carlos A. Zarate, MD, is Chief of the Experimental Therapeutics and Pathophysiology Branch at the National Institute of Mental Health. He is a fellow of the American College of Neuropsychopharmacology and member of the Society of Biological Psychiatry and the Society for Neuroscience. Dr. Zarate’s research focuses on the pathophysiology and development of novel therapeutics for treatment-resistant mood disorders as well as the study of biomarkers and neural correlates of treatment response.

Affiliations and expertise
Chief of the Experimental Therapeutics and Pathophysiology Branch at the National Institute of Mental Health, NIH, Bethesda, MD, USA